Research Progress of Microrna in The Treatment of Tumor Drugs
DOI:
https://doi.org/10.54097/rdf3w554Keywords:
MiRNA threapy; Cancer; Synthesis of miRNA; Delivery of miRNA.Abstract
MicroRNA (miRNA) has great potential for treating various diseases and has advantages that other treatment methods do not have when treating many diseases. MiRNA therapy has been applied to treat various diseases including obesity and cancer, and has shown significant efficacy. Many scientists are committed to developing new miRNA drugs in order to achieve better efficacy of miRNA therapy and more comprehensive coverage of diseases. This article describes the mechanism of action of miRNA and introduces and summarizes several necessary procedures for the development and production of miRNA drugs, including designing, producing miRNA, and designing ways to transport miRNA to target cells and tissues. Firstly, a synthesized pre-mRNAs or adenovirus-based mMIRs vector is designed in vitro, then, deliver them into host through viral or non-viral mediated system, finally, the miRNA could complement to specific gene by base-pairing, regulating the function of protein via interfering the expression of target genes. We hope that this article can contribute to the future development of miRNA drugs.
Downloads
References
[1] Friedman, R. C., Farh, K. K., Burge, C. B., & Bartel, D. P. (2009). Most mammalian mRNAs are conserved targets of microRNAs. Genome research, 19(1), 92–105. https://doi.org/10.1101/gr.082701.108
[2] Gregory, R. I., Yan, K. P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of microRNAs. Nature, 432(7014), 235–240. https://doi.org/10.1038/nature03120
[3] Nguyen, T. A., Jo, M. H., Choi, Y. G., Park, J., Kwon, S. C., Hohng, S., Kim, V. N., & Woo, J. S. (2015). Functional Anatomy of the Human Microprocessor. Cell, 161(6), 1374–1387. https://doi.org/10.1016/j.cell.2015.05.010
[4] Lund, E., Güttinger, S., Calado, A., Dahlberg, J. E., & Kutay, U. (2004). Nuclear export of microRNA precursors. Science (New York, N.Y.), 303(5654), 95–98. https://doi.org/10.1126/science.1090599
[5] Lee, H. Y., Zhou, K., Smith, A. M., Noland, C. L., & Doudna, J. A. (2013). Differential roles of human Dicer-binding proteins TRBP and PACT in small RNA processing. Nucleic acids research, 41(13), 6568–6576. https://doi.org/10.1093/nar/gkt361
[6] Krol, J., Loedige, I., & Filipowicz, W. (2010). The widespread regulation of microRNA biogenesis, function and decay. Nature reviews. Genetics, 11(9), 597–610. https://doi.org/10.1038/nrg2843
[7] Deng, Y., Zhang, J., Sun, X., Ma, G., Luo, G., Miao, Z., & Song, L. (2020). miR-132 improves the cognitive function of rats with Alzheimer's disease by inhibiting the MAPK1 signal pathway. Experimental and therapeutic medicine, 20(6), 159. https://doi.org/10.3892/etm.2020.9288
[8] Starlard-Davenport, A., Gu, Q., & Pace, B. S. (2022). Targeting Genetic Modifiers of HBG Gene Expression in Sickle Cell Disease: The miRNA Option. Molecular diagnosis & therapy, 26(5), 497–509. https://doi.org/10.1007/s40291-022-00589-z
[9] Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., Banham, A. H., Pezzella, F., Boultwood, J., Wainscoat, J. S., Hatton, C. S., & Harris, A. L. (2008). Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. British journal of haematology, 141(5), 672–675. https://doi.org/10.1111/j.1365-2141.2008.07077.x
[10] Mitchell, P. S., Parkin, R. K., Kroh, E. M., Fritz, B. R., Wyman, S. K., Pogosova-Agadjanyan, E. L., Peterson, A., Noteboom, J., O'Briant, K. C., Allen, A., Lin, D. W., Urban, N., Drescher, C. W., Knudsen, B. S., Stirewalt, D. L., Gentleman, R., Vessella, R. L., Nelson, P. S., Martin, D. B., & Tewari, M. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America, 105(30), 10513–10518. https://doi.org/10.1073/pnas.0804549105
[11] Arif, K. M. T., Elliott, E. K., Haupt, L. M., & Griffiths, L. R. (2020). Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets. Cancers, 12(10), 2922. https://doi.org/10.3390/cancers12102922
[12] Ho, P. T. B., Clark, I. M., & Le, L. T. T. (2022). MicroRNA-Based Diagnosis and Therapy. International journal of molecular sciences, 23(13), 7167. https://doi.org/10.3390/ijms23137167
[13] Turchinovich, A., Weiz, L., & Burwinkel, B. (2012). Extracellular miRNAs: the mystery of their origin and function. Trends in biochemical sciences, 37(11), 460–465. https://doi.org/10.1016/j.tibs.2012.08.003
[14] Uzuner E., Ulu G.T., Gürler S.B., Baran Y. The role of MIRNA in cancer: Pathogenesis, diagnosis, and treatment. Methods Mol. Biol. 2021;2257:375–422. doi: 10.1007/978-1-0716-1170-8_18.
[15] Di Martino M.T., Riillo C., Scionti F., Grillone K., Polerà N., Caracciolo D., Arbitrio M., Tagliaferri P., Tassone P. MIRNAs and lncrnas as novel therapeutic targets to improve cancer immunotherapy. Cancers. 2021;13:1587. doi: 10.3390/cancers13071587.
[16] Shah V., Shah J. Recent trends in targeting mirnas for cancer therapy. J. Pharm. Pharmacol. 2020;72:1732–1749. doi: 10.1111/jphp.13351.
[17] Parayath NN, Gandham SK, Amiji MM. Tumor-targeted miRNA nanomedicine for overcoming challenges in immunity and therapeutic resistance. Nanomedicine (Lond). 2022 Aug;17(19):1355-1373. doi: 10.2217/nnm-2022-0130. Epub 2022 Oct 18. PMID: 36255330; PMCID: PMC9706370.
[18] He L, He X, Lim LP et al. A miRNA component of the p53 tumor suppressor network. Nature. 447(7148), 1130–113 (2007).
[19] Raver-Shapira N, Marciano E, Neuru E et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 26(5), 731–43 (2007).
[20] Li XJ, Ren ZJ, Tang JH. MiR-34a: a potential therapeutic target in human cancer. Cell Death Dis. 5(7), e1327 (2014).
[21] Hermeking H. The miR-34 family in cancer and apoptosis. Cell Death Differ. 17(2), 193–9 (2010).
[22] Gregory PA, Bert AG, Paterson EL et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell. Biol. 10(5), 593–601 (2008).
[23] Pecot CV, Rupaimoole R, Yang D et al. Tumour angiogenesis regulation by the miR-200 family. Nat. Commun. 4, 2427 (2013).
[24] Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 100(1), 57–70 (2000).
[25] Arneth B. Tumor microenvironment. Medicina. 56(1), 15 (2019).
[26] Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 144(5), 646–674 (2011).
[27] Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 27(45), 5904–5912 (2008).
[28] Bejarano L, Jordāo MJ, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 11(4), 933–959 (2021).
[29] Cocks A, Del Vecchio F, Martinez-Rodriguez V, Schukking M, Fabbri M. Pro-tumoral functions of tumor-associated macrophage EV-miRNA. Semin Cancer Biol. 2022 Nov;86(Pt 1):58-63. doi: 10.1016/j.semcancer.2021.08.001. Epub 2021 Aug 8. PMID: 34371201; PMCID: PMC8821730.
[30] Wang M, Yu F, Ding H, Wang Y, Li P, Wang K. Emerging Function and Clinical Values of Exosomal MicroRNAs in Cancer. Mol Ther Nucleic Acids. 2019;16:791–804.
[31] Roy, B., Ghose, S., & Biswas, S. (2022). Therapeutic strategies for miRNA delivery to reduce hepatocellular carcinoma. Seminars in cell & developmental biology, 124, 134–144. https://doi.org/10.1016/j.semcdb.2021.04.006
[32] Iorio, M. V., & Croce, C. M. (2012). MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO molecular medicine, 4(3), 143–159. https://doi.org/10.1002/emmm.201100209
[33] Rupaimoole, R., Calin, G. A., Lopez-Berestein, G., & Sood, A. K. (2016). miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer discovery, 6(3), 235–246. https://doi.org/10.1158/2159-8290.CD-15-0893
[34] Bader A. G. (2012). miR-34 - a microRNA replacement therapy is headed to the clinic. Frontiers in genetics, 3, 120. https://doi.org/10.3389/fgene.2012.00120
[35] Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature reviews. Drug discovery, 16(3), 203–222. https://doi.org/10.1038/nrd.2016.246
[36] Rupaimoole, R., & Slack, F. J. (2017). MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nature reviews. Drug discovery, 16(3), 203–222. https://doi.org/10.1038/nrd.2016.246
[37] Bak, R. O., Hollensen, A. K., & Mikkelsen, J. G. (2013). Managing microRNAs with vector-encoded decoy-type inhibitors. Molecular therapy : the journal of the American Society of Gene Therapy, 21(8), 1478–1485. https://doi.org/10.1038/mt.2013.113
[38] Bak RO, Mikkelsen JG. miRNA sponges: soaking up miRNAs for regulation of gene expression. Wiley Inter Rev Rna. 2014;5:317–33.
[39] Shu, Y., Wu, K., Zeng, Z., Huang, S., Ji, X., Yuan, C., Zhang, L., Liu, W., Huang, B., Feng, Y., Zhang, B., Dai, Z., Shen, Y., Luo, W., Wang, X., Liu, B., Lei, Y., Ye, Z., Zhao, L., Cao, D., … He, T. C. (2018). A Simplified System to Express Circularized Inhibitors of miRNA for Stable and Potent Suppression of miRNA Functions. Molecular therapy. Nucleic acids, 13, 556–567. https://doi.org/10.1016/j.omtn.2018.09.025
[40] Wu, J., Bonsra, A. N., & Du, G. (2009). pSM155 and pSM30 vectors for miRNA and shRNA expression. Methods in molecular biology (Clifton, N.J.), 487, 205–219. https://doi.org/10.1007/978-1-60327-547-7_10
[41] Wu, P., Wilmarth, M. A., Zhang, F., & Du, G. (2013). miRNA and shRNA expression vectors based on mRNA and miRNA processing. Methods in molecular biology (Clifton, N.J.), 936, 195–207. https://doi.org/10.1007/978-1-62703-083-0_16
[42] Seyhan A. A. (2016). A multiplexed miRNA and transgene expression platform for simultaneous repression and expression of protein coding sequences. Molecular bioSystems, 12(1), 295–312. https://doi.org/10.1039/c5mb00506j
[43] Fan, J., Feng, Y., Zhang, R., Zhang, W., Shu, Y., Zeng, Z., Huang, S., Zhang, L., Huang, B., Wu, D., Zhang, B., Wang, X., Lei, Y., Ye, Z., Zhao, L., Cao, D., Yang, L., Chen, X., Liu, B., Wagstaff, W., … Yan, S. (2020). A simplified system for the effective expression and delivery of functional mature microRNAs in mammalian cells. Cancer gene therapy, 27(6), 424–437. https://doi.org/10.1038/s41417-019-0113-y
[44] Ruseska, I., & Zimmer, A. (2023). Cellular uptake and trafficking of peptide-based drug delivery systems for miRNA. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 191, 189–204. https://doi.org/10.1016/j.ejpb.2023.08.019
[45] Dasgupta, I., & Chatterjee, A. (2021). Recent Advances in miRNA Delivery Systems. Methods and protocols, 4(1), 10. https://doi.org/10.3390/mps4010010
[46] Schachner-Nedherer, A. L., Fuchs, J., Vidakovic, I., Höller, O., Schratter, G., Almer, G., Fröhlich, E., Zimmer, A., Wabitsch, M., Kornmueller, K., & Prassl, R. (2023). Lipid Nanoparticles as a Shuttle for Anti-Adipogenic miRNAs to Human Adipocytes. Pharmaceutics, 15(7), 1983. https://doi.org/10.3390/pharmaceutics15071983
[47] Fattore, L., Cafaro, G., Di Martile, M., Campani, V., Sacconi, A., Liguoro, D., Marra, E., Bruschini, S., Stoppoloni, D., Cirombella, R., De Nicola, F., Pallocca, M., Ruggiero, C. F., Castaldo, V., Catizone, A., Del Bufalo, D., Viglietto, G., Vecchione, A., Blandino, G., Aurisicchio, L., … Ciliberto, G. (2023). Oncosuppressive miRNAs loaded in lipid nanoparticles potentiate targeted therapies in BRAF-mutant melanoma by inhibiting core escape pathways of resistance. Oncogene, 42(4), 293–307. https://doi.org/10.1038/s41388-022-02547-9
[48] Avdoshin, A., Naumov, V., Ciacchi, L., C., Ignatov, S., & Köppen, S., (2023). Atomistic simulations of chitosan as a possible carrier system for miRNA transport. Materials advances, Vol.4 (4), p.1113-1124
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
